UNITED STATES SECURITIES AND EXCHANGE COMMISSION September 14, 2016

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioCryst Pharmaceuticals, Inc.

File No. 000-23186 - CF#34138

BioCryst Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 8, 2016.

Based on representations by BioCryst Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through April 11, 2026
Exhibit 10.2	through May 20, 2026
Exhibit 10.3	through June 30, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary